1. Home
  2. DNP vs NAMS Comparison

DNP vs NAMS Comparison

Compare DNP & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DNP Select Income Fund Inc.

DNP

DNP Select Income Fund Inc.

HOLD

Current Price

$11.10

Market Cap

4.2B

Sector

Finance

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$29.64

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DNP
NAMS
Founded
N/A
2019
Country
United States
Netherlands
Employees
N/A
100
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
3.7B
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
DNP
NAMS
Price
$11.10
$29.64
Analyst Decision
Strong Buy
Analyst Count
0
8
Target Price
N/A
$46.75
AVG Volume (30 Days)
677.4K
961.2K
Earning Date
01-01-0001
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$17.96
Revenue Next Year
N/A
$540.65
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.69
$21.14
52 Week High
$11.16
$42.21

Technical Indicators

Market Signals
Indicator
DNP
NAMS
Relative Strength Index (RSI) 61.14 41.00
Support Level $9.93 $29.23
Resistance Level $11.16 $37.29
Average True Range (ATR) 0.10 1.88
MACD -0.00 -0.42
Stochastic Oscillator 77.24 8.00

Price Performance

Historical Comparison
DNP
NAMS

About DNP DNP Select Income Fund Inc.

DNP Select Income Fund Inc is a closed-ended investment management fund. Its investment objectives are current income and long-term growth of income, with capital appreciation as a secondary objective. The Fund seeks to achieve its investment objectives by investing mainly in a diversified portfolio of equity and fixed-income securities of companies in the public utilities industry. Under normal market conditions, more than 65% of the Fund's total assets are invested in securities of public utility companies engaged in the production, transmission, or distribution of electric energy, gas, or telephone services.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: